Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis.

Multiple sclerosis is a T cell-mediated demyelinating disease of the central nervous system. Interleukin-17-producing T helper cells, named Th17 cells, represent a novel CD4+ T cell effector subset involved in the response against extracellular pathogens. In addition, Th17 cells are pathogenic in several animal models of autoimmune disease, including the animal model for multiple sclerosis, but their function in multiple sclerosis remains to be elucidated. In this study, we analysed the frequency and the phenotype of Th17 cells in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients. We show that the frequency of Th17 cells is significantly higher in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis during relapse, in comparison to relapsing-remitting patients in remission or to patients with other non-inflammatory neurological diseases. Similarly, in patients with clinically isolated syndrome during their first neurological episode, Th17 cells are more abundant than in clinically isolated syndrome patients with no acute symptoms. Patients with inflammatory neurological diseases other than multiple sclerosis also showed increased frequency of Th17 cells compared to patients with no inflammatory diseases. To assess a potential pathological impact of Th17 cells in disease, we generated T cell clones from the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. We found that Th17 clones expressed higher basal levels of the activation markers CD5, CD69, CD2 and human leukocyte antigen-DR as well as of the CD28-related family of co-stimulatory molecules, when compared to Th1 clones, and confirmed these findings with ex vivo human T cells. Molecules involved in T cell adhesion to endothelium, such as CD49d, CD6 and the melanoma cell adhesion molecule, were also more abundant on the Th17 than on the Th1 cells. Furthermore, functional assays showed that Th17 clones were more prone than Th1 clones to melanoma cell adhesion molecule-mediated adhesion to endothelial cells, and that Th17 cells had a higher proliferative capacity and were less susceptible to suppression than Th1 cells. Altogether our data suggest that Th17 cells display a high pathogenic potential and may constitute a relevant pathogenic subset in multiple sclerosis.

[1]  Eva Tolosa,et al.  Phenotypical Characterization of Human Th17 Cells Unambiguously Identified by Surface IL-17A Expression1 , 2009, The Journal of Immunology.

[2]  Yuhong Yang,et al.  T-bet is essential for encephalitogenicity of both Th1 and Th17 cells , 2009, The Journal of experimental medicine.

[3]  B. Engelhardt,et al.  C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE , 2009, Nature Immunology.

[4]  M. Kaplan,et al.  IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage1 , 2008, The Journal of Immunology.

[5]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[6]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.

[7]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[8]  Danica Stanimirovic,et al.  Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system , 2008, Nature Immunology.

[9]  S. Ward.  Faculty Opinions recommendation of Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. , 2008 .

[10]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[11]  Dominique Dunon,et al.  Dual Role of Melanoma Cell Adhesion Molecule (MCAM)/CD146 in Lymphocyte Endothelium Interaction: MCAM/CD146 Promotes Rolling via Microvilli Induction in Lymphocyte and Is an Endothelial Adhesion Receptor1 , 2007, The Journal of Immunology.

[12]  Nathalie Arbour,et al.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.

[13]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[14]  R. Nussenblatt,et al.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 , 2007, Nature Medicine.

[15]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[16]  H. Weiner,et al.  IL-23 Is Increased in Dendritic Cells in Multiple Sclerosis and Down-Regulation of IL-23 by Antisense Oligos Increases Dendritic Cell IL-10 Production , 2006, The Journal of Immunology.

[17]  R. Simon,et al.  Redundancy in Antigen-Presenting Function of the HLA-DR and -DQ Molecules in the Multiple Sclerosis-Associated HLA-DR2 Haplotype1 , 2006, The Journal of Immunology.

[18]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[19]  R. Wu,et al.  Up-Regulation of CC Chemokine Ligand 20 Expression in Human Airway Epithelium by IL-17 through a JAK-Independent but MEK/NF-κB-Dependent Signaling Pathway1 , 2005, The Journal of Immunology.

[20]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[22]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[23]  David H. Miller,et al.  Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis , 2005, Multiple sclerosis.

[24]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[25]  R. Nurieva,et al.  Regulation of immune and autoimmune responses by ICOS. , 2003, Journal of Autoimmunity.

[26]  G. Bernardi,et al.  Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS , 2003, Journal of leukocyte biology.

[27]  M. Kamoun,et al.  Induction of Experimental Autoimmune Encephalomyelitis in IL-12 Receptor-β2-Deficient Mice: IL-12 Responsiveness Is Not Required in the Pathogenesis of Inflammatory Demyelination in the Central Nervous System1 , 2003, The Journal of Immunology.

[28]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.

[29]  B. '. ’t Hart,et al.  Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody1 , 2002, Journal of Immunology.

[30]  B. Becher,et al.  Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. , 2002, The Journal of clinical investigation.

[31]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[32]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[33]  W. Oertel,et al.  Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor Vbeta analysis. , 2000, Journal of immunological methods.

[34]  M. Laan,et al.  Airway neutrophils and interleukin-17. , 2000, The European respiratory journal.

[35]  P. Kivisäkk,et al.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.

[36]  C. Albanesi,et al.  IL-17 Is Produced by Nickel-Specific T Lymphocytes and Regulates ICAM-1 Expression and Chemokine Production in Human Keratinocytes: Synergistic or Antagonist Effects with IFN-γ and TNF-α , 1999, The Journal of Immunology.

[37]  C. Albanesi,et al.  IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. , 1999, Journal of immunology.

[38]  M. Esiri,et al.  The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.

[39]  S. Shaw,et al.  A fluorogenic assay of endogenous phosphatase for assessment of cell adhesion. , 1996, Journal of immunological methods.

[40]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[41]  S. Karlik,et al.  A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis , 1995, Journal of Neuroimmunology.

[42]  S. Karlik,et al.  A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. , 1995, Journal of neuroimmunology.

[43]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.